Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma

Cancer

Volumn 94, Issue 4, 2002, Pages 879-888

  Kostakoglu, Lale ^a,c   Leonard, John P ^a,b   Kuji, Ichiei ^a   Coleman, Morton ^a,b   Vallabhajosula, Shankar ^a   Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

F 18 fluorodeoxyglucose; Ga 67 imaging; Hodgkin disease; Lymphoma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 67;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037083501     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10336     Document Type: Article

References (37)

1. The lymphomas
2. Prognostic factors in Hodgkin's disease; Implications for modern treatment
3. Computed tomography of abdominal para-aortic lymph node disease: Preliminary observation with a 6 second scanner
4. A comparison of gallium-67 single photon emission computed tomography and computed tomography in mediastinal Hodgkin's disease
5. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy
6. Magnetic resonance imaging and Ga-67 scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study
7. Gallium-67 imaging in monitoring lymphoma response to treatment
8. Validation of gallium-67 citrate single photon emission tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum
9. Ga-67 scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma
10. The value of gallium imaging after therapy for Hodgkin's disease
11. 67Ga scintigraphy after one cycle of chemotherapy
12. The role of gallium-67 in the clinical evaluation of cancer
13. 18F] fluoro-2-deoxy-D- glucose: Correlation with CT
14. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study
15. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
16. Lymphoma: Role of whole body 2-deoxy-2 [F-18] fluoro-D-glucose (FDG) PET in nodal staging
17. Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment
18. 18F-FDG to detect residual disease after therapy for malignant lymphoma
19. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
20. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
21. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
22. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
23. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease
24. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis
25. Positron emission tomography using fluorine-18-fluorodeoxy-glucose in malignant lymphoma; A comparison with proliferative activity
26. Gallium-67 as a tumor-seeking agent in lymphomas - A review
27. A fluorinated glucose analog, 2-fluoro-2deoxy-D-glucose (F-18)
28. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma
29. Mechanism involved in gallium-67 (Ga-67) uptake by human lymphoid cell lines
30. The role of gallium-67 in the clinical evaluation of cancer
31. Validation of gallium-67-citrate singlephoton emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum
32. Comparison of gallium-67 citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma
33. Proliferative activity and DNA index do not significantly predict survival in primary central nervous system lymphoma
34. Localization of the cell proliferation and apoptosisassociated CAS protein in lymphoid neoplasms
35. Predicting malignancy grade with PET in non-Hodgkin's lymphoma
36. Extranodal malignant lymphoma: Detection with FDG PET versus CT
37. F-18-FDG positron imaging in oncological patients: Gamma camera coincidence detection versus dedicated PET